Feedback Share Price (FDBK)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Feedback Plc	LSE:FDBK	London	Ordinary Share	GB0003340550	ORD 0.25P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	2.00p	1.95p	2.05p	2.00p	2.00p	2.00p	340,108	07:53:17

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Electronic & Electrical Equipment	0.4	-0.3	-0.1	-	4.93

Related Shares
Halma (HLMA), Renishaw (RSW), Ross (RGP), Pipehawk (PIP)

Feedback (FDBK) Latest News

Feedback News

Date	Time	Source	Headline
14/9/2017	07:01	UKREG	Feedback PLC Holding(s) in Company
31/7/2017	17:00	UKREG	Feedback PLC Total Voting Rights
28/7/2017	11:27	ALNC	Feedback Appoints GE-Linked Chinese Distributor For TexRAD Software
28/7/2017	10:55	ALNCF	Alliance News Flash Headline
28/7/2017	10:53	RNSNON	Feedback PLC CCI Exclusive Distributor agreement with Boya
30/6/2017	14:21	UKREG	Feedback PLC Holding(s) in Company
30/6/2017	12:41	UKREG	Feedback PLC Issue of Equity
08/6/2017	13:34	ALNC	Feedback Signs Exclusive TexRAD Distributor Deal Covering South Korea
08/6/2017	13:15	RNSNON	Feedback PLC CCI Exclusive Distributor Agreement with Korea ISG
08/6/2017	13:11	UKREG	Feedback PLC Directorate Change

More Feedback News

Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback Forums and Chat

Date	Time	Title	Posts
18/9/2017	08:53	**Feedback PLC**	1,176
03/2/2010	11:50	Feedback looks interesting - could easily be a ten bagger over next year	396
03/9/2002	11:53	ainsley long .........................quick shart it	2
21/3/2002	17:36	FEEDBACK+1.5p -GOOD VOLUME-Reversing trend	10

Add a New Thread

Feedback (FDBK) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
10:36:06	1.95	75,000	1,462.50	O
07:57:55	1.99	50,000	995.00	O
07:48:56	1.98	100,000	1,980.00	O
07:36:02	1.95	15,675	305.66	O
07:34:34	1.95	75,000	1,462.50	O

View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

Date	Subject
21/9/2017 09:20	Feedback Daily Update: Feedback Plc is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 2p. Feedback Plc has a 4 week average price of 1.88p and a 12 week average price of 1.88p. The 1 year high share price is 5.13p while the 1 year low share price is currently 1.38p. There are currently 246,416,584 shares in issue and the average daily traded volume is 1,203,628 shares. The market capitalisation of Feedback Plc is £4,928,331.68. Read Full Thread Reply
20/7/2017 15:29	lr2: You will likely get the same, standard response that everyone else got. "The company has received several communications recently from shareholders expressing frustration at the drop in share price linked to ex-director’s dealing and to the lack of news flow on the CE mark. We cannot comment on the actions of ex directors or individual shareholders beyond what has already been announced. On progress with the CE mark, the team at Cambridge Computed Imaging responsible for completing this task have found the final stages to be slower than anticipated. There are, however, no major impediments foreseen that will prevent its completion, it is just taking a little longer. We are very confident that we will be in a position to obtain the the CE mark soon." Kind regards, Dr. Alastair J Riddell Chairman Feedback plc Read Full Thread Follow Reply
07/10/2015 21:56	lr2: Feedback PLC, Don’t You Hate the Small Profit-Takers? Http://www.branduk.net/malcolm-stacey-of-shareprophets-feedback-plc-dont-you-hate-the-small-profit-takers/ Hello Share Bunnies. There was some interesting share movements after all the good news came out for Feedback (FDBK), the minnow capitalised at a mere £5 million. This firm which makes software to help in assessing cancers and other serious illnesses has been recording some big progress. The latest news to come in was that the National Health Service’s research arm has produced ‘an alert’ to the affect that this company is worth looking at. The share price put on 15%. It kept that level for most of the morning. Then the price began stepping up. There were small twitches until the golden share reached nearly a 50% rise on the day. This put Feedback at the top of the overall winners board. But not for long. The zenith proved to be a spike and the share inched down again to end the day at just 15% up. I checked the number of buys and sells throughout the day, and at no point did purchases exceed the sales. This rise and fall pattern is so common for penny shares these days. And I think we all know what’s going on.There is a large army out there who will take a profit, no matter what the great future might lie in store for the company. Feedback may not yet have recorded a recent profit, but it already nets £300,000 every 6 months by way of royalties and as their software is so desirable to find and treat serious cancers, I cannot see it failing to be a tasty go-er in the near future. Yet, so many holding the share are willing to take a short term profit. And they do that even though the spread is, as I look now, 20%. I think such short-term strategies are a mistake. They won’t realise much cash, because I notice the parcels of shares sold were largely tiny, many under £300. This could be a multi-bagger. I’m not daft enough to say that’s certain, or even probable, but I’m buying the shares and staying in for a few months at least. But what the heck? They say it’s never wrong to take a profit, and that does take a bit of arguing against. But personally I prefer a big profit to a small one. Time now for sampling duty – at the Punter’s Return. Read Full Thread Follow Reply
06/10/2015 10:16	lr2: Thanks Blueball. I posted the NHS alert on here last Friday night (post #865) and nobody seemed to register the importance of it other than Britstox. Just as well Feedback got around to announcing the news today as my post had no effect on the share price. :) Read Full Thread Follow Reply
05/6/2015 09:05	the stigologist: the ultra small round that fraudy took part in was simply designed to pump the share price i suspect Read Full Thread Follow Reply
04/6/2015 13:13	sja123: Might be worth bearing in mind that the last time the company was requested to put out an RNS stating there was "no known reason for share price movement", they went on to make three or four further announcements in a couple of weeks, including deals in Korea, Brisbane, Texas and with Oxford Stone.... Just saying....it doesn't necessarily mean a jot.... and something is driving the volume here today IMO.... We'll see...but I'm quite happy to hold with what is already out there.... Read Full Thread Follow Reply
15/5/2015 13:33	norbert colon: Stig/21. The good thing about these BBs is the fact that they are an open forum for investors, traders and in fact anyone to comment on a particular share / company and generally it's great to get the mixed views of all involved. All I would add re: some of the comments in this board from yourselves is that: 1) the RNS re: share price movement has to be read in the context that any RNS that does not specify contract values and relate them to forecasts for the business are just business as usual. All the recent announcement are business as usual in some respect as they are a function of the company trading and undertaking business; they are not YET material with respect to orders etc and hence I understand why they released that statement although I agree that given their very small mcap and early start-up stature, the flurry of positive news does seem ironic / coincidental. 2) Let's not call others on this board liars or delve to similar levels. Go short if you think FDBK is all hot air. Anyway, enjoy the weekend all and let's all hope for further news. Nobby Read Full Thread Follow Reply
26/4/2015 12:31	lr2: Bayer Healthcare Pharmaceuticals, Inc. / Bayer Schering Pharma are sponsoring the following "Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX". HTTP://clinicaltrials.gov/ct2/show/study/NCT02425683#contacts This US based Colorectal Cancer study was posted up on the US Government National Institutes of Health site last Thursday (the same day as the share price movement RNS). It is still in the recruiting participants phase. What makes this particular study interesting, I reckon, is the following paragraph in the Detailed Description section. "In addition, evaluating the Texture (spatial variations in pixel intensity) in computed tomography (CT) scans might help predict the risk of recurrence. Therefore, CT disks will be sent to Imaging Endpoints Core Lab, Scottsdale, AZ, where the TexRAD platform (a software algorithm) will be used for analysis." This could be a significant breakthrough for FDA approval. Read Full Thread Follow Reply
23/4/2015 12:29	21trader: Who's going to buy their shares if they issue 2 bits of good news and then say no reason for the rise. It's only gone from 1.5p offer to 2.5p offer the whole idea of good news is to increase the share price. Now if it was 4p I could understand it but the price was not moving at the time of Rns and there was little action in the previous 2 hours. Read Full Thread Follow Reply
19/4/2015 20:10	alicia1983: Before the kidney stone trial announcement, the share price was 1-1-5p. Since the collaboration with the Oxford Stone Group RNS was released, the share price has moved to 1.5-1.8. From the RNS: "In the UK, an estimated 85,000 patients attend hospital with kidney stones each year..........which patients will benefit from lithotripsy would help to streamline treatment pathways and better allow clinicians to advise patients in choosing the right option for them. Similarly, using a non-invasive tool to better evaluate the composition of the stone facilitates personalised advice". But according to this: hxxp://parathyroid.com/kidney-stones.htm kidney stones are common throughout the world (between 3% and 5% of the population) so the numbers of potential beneficiaries (if it works) is quite appreciable. There is no guidance from the Company about what all this might mean, if anything, for potential revenues so shareholders have to form their own views - does anyone have any ideas? Read Full Thread Follow Reply
16/4/2015 15:04	maxy26: This is hardly traded and directors own more than half the shares so it is not surprising that movements, when they occur are sharp and sudden. The technology is esoteric - if anyone can comprehend it - so if anything interesting is happening it is probably understandable only by the cognoscenti. The share price tells the story well enough probably.... Read Full Thread Follow Reply

Feedback share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:42 V: D:20170921 16:01:39